Trial record 1 of 4 for:    MG01CI
Previous Study | Return to List | Next Study

Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcobra Ltd.
ClinicalTrials.gov Identifier:
NCT01685281
First received: September 12, 2012
Last updated: January 13, 2014
Last verified: January 2014
  Purpose

study objectives are to compare the efficacy, safety and tolerability of two doses of MG01CI (1400 mg and 700 mg) to Placebo for the treatment of symptoms in adults diagnosed with PI-ADHD.

subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows:

  1. week 1:1400 mg, week 2:700 mg, week 3:placebo
  2. week 1:700 mg,week 2: placebo,week 3:1400 mg
  3. week 1: placebo, week2:1400 mg, week 3 700 mg

The study will consist of three periods: a screening period of up to one week, a 3-week double-blind treatment period, and a one-week safety follow-up period.


Condition Intervention Phase
ADHD Predominantly Inattentive Type
Drug: Metadoxine (MG01CI)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

Resource links provided by NLM:


Further study details as provided by Alcobra Ltd.:

Primary Outcome Measures:
  • Change in TOVA ADHD score from Screening/Baseline to 4 hours post-dose; [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    TOVA® is a computerized test that provides information about an individual's sustained attention, speed and consistency of responding, and behavioral self-regulation and executive functioning


Secondary Outcome Measures:
  • Change in CANTAB sub-scores from baseline (Visit 2) to 4 hours post-dose; [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The CANTAB is a computerized test assessing the key cognitive deficits present in ADHD. Sub-scores will include spatial working memory (SWM), stop signal task (SST), rapid visual information processing (RVP), and reaction time (RTI).

  • Change in TOVA sub-scores from Screening/Baseline to 4 hours post-dose [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Number of participants who withdrew early from the study due to AE [ Time Frame: 5 weeks ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • Number of Adverse Events [ Time Frame: 5 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 36
Study Start Date: August 2013
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Metadoxine (MG01CI) 1400 mg
single dose of Metadoxine (MG01CI) 1400 mg
Drug: Metadoxine (MG01CI)
MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
Other Name: metadoxil
Active Comparator: Metadoxine (MG01CI) 700 mg
Single dose of Metadoxine (MG01CI) 700 mg
Drug: Metadoxine (MG01CI)
MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
Other Name: metadoxil
Placebo Comparator: Placebo
Single dose of Placebo
Drug: Placebo
Placebo tablets will be similar in appearance (color and size) to the investigational product

Detailed Description:

The purpose of this dose finding study is to compare two doses of MG01CI (1400 mg and 700 mg) to Placebo, in adult subjects with PI-ADHD. A crossover study design will allow evaluation of safety/tolerability and efficacy using validated computerized tests.

subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows:

  1. week 1:1400 mg, week 2:700 mg, week 3:placebo
  2. week 1:700 mg,week 2: placebo,week 3:1400 mg
  3. week 1: placebo, week2:1400 mg, week 3 700 mg

Overview of Study Visits

Screening Period:

Visit 1 - Screening/Baseline Visit (up to 7 days prior to dosing)

Treatment Period:

Visit 2 - Day 0 (Randomization Visit) Visit 3 - Day 7 ± 3 days Visit 4 - Day 14 ± 3 days Visit 5 - Day 21 ± 3 days

Follow-up period:

Visit 6 - Day 28 ± 3 days

Study duration for each subject will be up to 35 days .

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult men and women, 18 to 55 years old
  2. Diagnosed with predominantly inattentive ADHD based on DSM-IV criteria for ADHD as assessed by the Adult ADHD Clinician Diagnostic Scale (ACDS V1.2);
  3. Clinical severity of at least a moderate level (Clinical Global Impression score of 4 or above)
  4. TOVA ADHD score of -1.8 or below at Screening /Baseline
  5. Women with childbearing potential must agree to use effective contraceptive and have negative urine pregnancy test at screening visit
  6. Able to attend the clinic regularly and reliably
  7. Able to swallow tablets/capsules
  8. Able to understand, read, write and speak Hebrew fluently to complete study related materials
  9. Able to understand and sign written informed consent to participate in the study

Exclusion Criteria:

  1. Subjects with ADHD not otherwise specified (NOS) diagnosis
  2. Subjects with combined type or predominantly hyperactive impulsive ADHD diagnoses
  3. Subjects with current Axis I diagnosis on SCID
  4. Subjects with lifetime bipolar or psychosis
  5. Subjects in treatment for Axis I disorders, even if the disorder is remitted
  6. Subjects who were non-responders to at least two adequately administered ADHD treatments
  7. Subjects with any medical or psychiatric condition common diseases such as hypertension, type 2 diabetes mellitus, hyperlipidemia, etc. are allowed per the Investigator's judgment, as long as they are stable and controlled by medical therapy that is constant for at least 8 weeks prior to randomization and throughout the study
  8. Any prescription or non-prescription ADHD medications during the 14 days (for stimulants) or 28 days (for non-stimulants and other psychotropics) prior to the screening visit
  9. Known or suspected HIV-positive or with advanced diseases such as AIDS, Hepatitis C, Hepatitis B or tuberculosis
  10. History of allergy or sensitivity to B complex vitamins
  11. History or suspicion of PDD, NLD or other psychotic conditions
  12. Use of Vitamin B throughout the study (either alone or in any multi-vitamin)
  13. Use of ADHD medications throughout the study
  14. Use of any psychotropic medications throughout the study
  15. Use of investigational medication/treatment in the past 30 days prior to the screening visit
  16. Use of any medication or food supplement unless cleared by the medical monitor during the 14-day period before randomization
  17. Current (or history within the last 6 months) of drug dependence or substance abuse disorder according to DSM-IV-TR criteria (excluding nicotine). Subjects should also agree to refrain from significantly changing consumption of caffeine during the study.
  18. Suicidality, defined as active ideation, intent or plan, or any lifetime attempt (CSSRS)
  19. Subjects who cannot complete any study instruments or questionnaires
  20. Any relation to the Sponsor, Investigator or study staff
  21. Any condition, which in the opinion of the Principal Investigator would place the subject at risk or influence the conduct of the study or interpretation of results, including (but not limited to) abnormally low intellectual capacity.
  22. Subjects who cannot fully comprehend the implications of the protocol or comply with its requirements or are capable to follow the study schedule for any reason
  23. Women of childbearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agree to use a reliable method of birth control (e.g., oral contraceptives or Norplant®; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; partner with vasectomy; or abstinence) during the study. Note that this inclusion criterion applies only to females of childbearing potential. Females of childbearing potential are defined as women not surgically sterilized and between menarche and 2 years post-menopause
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01685281

Locations
Israel
Geha Medical Centre
Petah Tiqva, Israel
Sponsors and Collaborators
Alcobra Ltd.
Investigators
Principal Investigator: Iris Manor, Dr. Geha Medical center
  More Information

No publications provided

Responsible Party: Alcobra Ltd.
ClinicalTrials.gov Identifier: NCT01685281     History of Changes
Other Study ID Numbers: AL011
Study First Received: September 12, 2012
Last Updated: January 13, 2014
Health Authority: Israel: Ministry of Health

Keywords provided by Alcobra Ltd.:
ADHD , Inattention

Additional relevant MeSH terms:
Hyperkinesis
Attention Deficit Disorder with Hyperactivity
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Metadoxine
Alcohol Deterrents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014